{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:57:37Z","timestamp":1793861857644,"version":"4.6.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203331"],"award-info":[{"award-number":["NIHR203331"]}],"id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","award":["QoC 010"],"award-info":[{"award-number":["QoC 010"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1136\/ard-2024-226430","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:27:43Z","timestamp":1728653263000},"page":"29-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":292,"title":["EULAR recommendations for the treatment of systemic sclerosis: 2023 update"],"prefix":"10.1016","volume":"84","author":[{"given":"Francesco","family":"Del Galdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"\u010coli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossra A.","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Balbir-Gurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Ananyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rednic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tarasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedrag","family":"Ostojic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"El Aoufy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otylia","family":"Kowal-Bielecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Mueller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-226430_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226430_bib2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/ard-2024-226430_bib3","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2665-9913(20)30007-2","article-title":"Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials","volume":"2","author":"Del Galdo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2023.1729","article-title":"Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database","volume":"159","author":"Lescoat","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2024-226430_bib5","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","author":"Parodis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/annrheumdis-2023-eular.4742","article-title":"POS1260\u2005SYSTEMATIC literature review for the 2023 update of eular recommendations for the treatment of systemic sclerosis","volume":"82","author":"Lescoat","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib10","series-title":"OCEBM levels of evidence \u2014 centre for evidence-based medicine (cebm)","year":"2023"},{"key":"10.1136\/ard-2024-226430_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard-2024-226430_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/art.40377","article-title":"Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3899\/jrheum.100358","article-title":"Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension","volume":"37","author":"Rosato","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-015-0558-9","article-title":"Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial","volume":"17","author":"Bose","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226430_bib17","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-226430_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5301\/jsrd.5000232","article-title":"Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up","volume":"2","author":"Seibold","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1136\/ard-2024-226430_bib19","first-page":"S872","article-title":"ACR ANNUAL SCIENTIFIC MEETING Abstract #2086: Efficacy of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Double Blind Randomized Placebo Controlled Parallel Group Multicentric Study","volume":"62","author":"Agarwal","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226430_bib20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226430_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib24","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2024-226430_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3899\/jrheum.180595","article-title":"Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study","volume":"47","author":"Pesta\u00f1a-Fern\u00e1ndez","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.39478","article-title":"Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension","volume":"68","author":"Lammi","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14397595.2019.1704125","article-title":"The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis","volume":"31","author":"Lei","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1136\/ard-2024-226430_bib29","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004757","article-title":"Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?","volume":"11","author":"Khan","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1136\/ard-2024-226430_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-017-1341-x","article-title":"Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension","volume":"19","author":"Morrisroe","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226430_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/jcpt.13621","article-title":"Angiotensin-converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta-analysis","volume":"47","author":"Xiong","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1136\/ard-2024-226430_bib36","first-page":"5095","article-title":"Upper gastrointestinal involvement in systemic sclerosis: Findings in a real-life setting","volume":"18","author":"Petcu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1136\/ard-2024-226430_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13247","article-title":"Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients","volume":"30","author":"Stern","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1136\/ard-2024-226430_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","article-title":"Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial","volume":"56","author":"Foocharoen","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226430_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/2050640614560453","article-title":"Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study","volume":"3","author":"Karamanolis","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"10.1136\/ard-2024-226430_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","article-title":"Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study","volume":"19","author":"Vigone","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226430_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-021-02506-x","article-title":"Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis","volume":"23","author":"Zampatti","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226430_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3899\/jrheum.110225","article-title":"Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"38","author":"Khanna","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib43","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226430_bib44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226430_bib46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib47","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226430_bib49","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis","volume":"40","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib50","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226430_bib51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226430_bib52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2024-226430_bib53","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226430_bib55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226430_bib56","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226430_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226430_bib58","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226430_bib60","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226430_bib62","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib63","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-226430_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226430_bib65","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41409-021-01355-1","article-title":"Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score","volume":"56","author":"Ait Abdallah","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1136\/ard-2024-226430_bib66","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-226430_bib67","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience","volume":"50","author":"Castellv\u00ed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-226430_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator\u2010Initiated, Multicenter, Double\u2010Blind, Randomized, Placebo\u2010Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2024-226430_bib69","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2024-226430_bib71","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/rheumatology\/kead457","article-title":"Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy","volume":"63","author":"Keret","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-226430_bib72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226430_bib74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","article-title":"Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire","volume":"81","author":"Becker","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724005843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724005843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-226430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:59:31Z","timestamp":1777384771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724005843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0003496724005843"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-226430","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}